Paolo Corradini

Paolo Corradini

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 261 publications

Ringing the Bell in Cancer Care: A Scoping Review of Patients', Caregivers', and Healthcare Professionals' Experiences and Implications for Oncology Nursing.

Ringing the Bell in Cancer Care: A Scoping Review of Patients', Caregivers', and Healthcare Professionals' Experiences and Implications for Oncology Nursing.

Journal: Cancer nursing
Published: August 11, 2026

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.

Journal: Blood advances
Published: April 16, 2026

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

Real-world CAR-T practice patterns in patients with mantle cell lymphoma: an international survey on behalf of the EBMT lymphoma working party.

Journal: Bone marrow transplantation
Published: April 12, 2026

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Increased risk of secondary malignancies after autologous transplantation in R/R follicular lymphoma: Long-term results from FIL-FLAZ12 Phase III trial.

Journal: HemaSphere
Published: April 02, 2026

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Frontline Nilotinib Versus Dasatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Propensity Score Analysis Based on Agenzia Italiana del Farmaco Monitoring Registries.

Journal: Clinical lymphoma, myeloma & leukemia
Published: March 15, 2026

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Occult hepatitis B virus infection status is not associated with impaired efficacy of anti-CD19 CAR-T-cell therapy for lymphoma and shows a distinct immune toxicity profile: Results from the CART-SIE study.

Journal: HemaSphere
Published: February 05, 2026

An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma.

An Italian Delphi consensus on the current and future burden and clinical management of lenalidomide-refractory multiple myeloma.

Journal: Leukemia research
Published: February 02, 2026

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

Journal: The Lancet. Haematology
Published: December 28, 2025

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.

Journal: The Lancet. Haematology
Published: December 16, 2025

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 18, 2025

Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study.

Longitudinal Monitoring of Measurable Residual Disease in Chronic Lymphocytic Leukemia Patients Treated With Venetoclax: Results of a Prospective Multicenter Real-Life Study.

Journal: Hematological oncology
Published: November 15, 2025

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 20, 2025
Showing 1-12 of 261

Last Updated: 09/26/2026